The authors constructed a Markov model as part of a systematic review of cervical cytology conducted at the Duke University Evidence-based Practice Center (Durham, North Carolina) between October 1997 and September 1998. The model incorporated states for human papillomavirus infection (HPV), low-and high-grade squamous intraepithelial lesions, and cervical cancer stages t-IV to simulate the natural history of HPV infection in a cohort of women from ages 15 to 85 years. The age-specific incidence rate of HPV, and regression and progression rates of HPV and squamous intraepithelial lesions, were obtained from the literature. The effects of varying natural history parameters on cervical cancer incidence were evaluated by using sensitivity analysis. The base-case model resulted in a lifetime cervical cancer risk of 3.67% and a lifetime cervical cancer mortality risk of 1.26%, with a peak incidence of 81/100,000 at age 50 years. Age-specific distributions of precursors were similar to reported data. Lifetime risk of cancer was most sensitive to the incidence of HPV and the probability of rapid HPV progression to high-grade lesions (two-to threefold variations in risk). The model approximates the age-specific incidence of cervical cancer and provides a tool for evaluating the natural history of HPV infection and cervical cancer carcinogenesis as well as the effectiveness and cost-effectiveness of primary and secondary prevention strategies. Am J Epidemiol 2000; 151:1158-71. cervical intraepithelial neoplasia; cervix neoplasms; models, theoretical; papillomavirus, human Carcinoma of the cervix is one of the most common malignancies of women in many parts of the world. Secondary prevention by using cervical smears to detect preinvasive and early invasive disease has led to significant reductions in both incidence and mortality in many countries (1). In the United States, both incidence and mortality have declined steadily; Surveillance, Epidemiology, and End Results (SEER) registry data show a 43 percent decrease in incidence and a 45.9 percent decrease in mortality from 1973 to 1995 (2). Such reductions have not been observed in countries in which cytologic screening is not widely available (3).
Carcinoma of the cervix is one of the most common malignancies of women in many parts of the world. Secondary prevention by using cervical smears to detect preinvasive and early invasive disease has led to significant reductions in both incidence and mortality in many countries (1) . In the United States, both incidence and mortality have declined steadily; Surveillance, Epidemiology, and End Results (SEER) registry data show a 43 percent decrease in incidence and a 45.9 percent decrease in mortality from 1973 to 1995 (2) . Such reductions have not been observed in countries in which cytologic screening is not widely available (3).
Although there have been no randomized trials of the effectiveness of cervical cytologic screening in preventing mortality from cervical cancer, there is wide consensus based on results of historical series and case-control studies that screening does result in significant decreases in incidence and mortality (4) . However, considerable controversy remains about the optimal frequency for such testing, the potential role of adjunctive technologies for improving the sensitivity of screening, and the appropriate management of lowgrade lesions that may be preinvasive. In addition, although there is general agreement on the broad outlines of the natural history of cervical cancer (5, 6) , uncertainty exists about the specifics of many of the elements that contribute to natural history. These issues have been approached primarily with modeling (7) (8) (9) (10) (11) (12) (13) (14) .
Comprehensive simulation models enable integration of evidence from a wide variety of sources to evaluate natural history as well as prevention and treatment strategies, and they have been used to evaluate strategies for preventing stroke (15) . As part of a comprehensive review of the effectiveness of both conventional cervical cytologic screening and new adjunctive technologies (16) performed at the Duke University Center for Clinical Health Policy Research (Durham, North Carolina), we took a similar approach, using simulation modeling to integrate available evidence on strategies for preventing cervical cancer. This review, funded by the US Agency for Health Care Policy and Research as part of its Evidence-based Practice Centers program (a group of 12 sites in the United States and Canada that conduct systematic reviews and data synthesis on topics designated by the agency), included a meta-analysis of studies on the sensitivity and specificity of the conventional cervical smear, an analysis of costs associated with screening and treatment for cervical cancer and preinvasive lesions in the United States, and a cost-effectiveness analysis of screening strategies to prevent cervical cancer. In this paper, we present a model of the natural history of cervical cancer that builds on both the work of previous authors and recent epidemiologic evidence to predict the age-specific incidence of cervical cancer in unscreened populations and can be used to assess the potential impact of preventive strategies.
MATERIALS AND METHODS
We constructed a 19-state Markov model (17) by using DATA 3.0 software (TreeAge Software, Williamstown, Massachusetts). In a Markov model, the conditional distribution of the outcomes given an exposure status depends on prior outcome observations only. Our model follows a simulated cohort of women from ages 15 through 85 years. The probability of moving from one state to another (e.g., from normal to human papillomavirus (HPV) infected) during a given Markov cycle (e.g., a 1-year time period) is determined by the modeler; typically, these probabilities are state and often cycle specific. States and allowed transitions are shown in table 1 and figure 1. The model is described in detail in the final evidence report prepared by Duke University (16) , and copies of the software program are available from the authors on request. Because the model generates probabilities, the cohort can be any size; for a person, the model generates lifetime probabilities of being in a given health state. Acquisition of HPV is based on age-specific incidence rates. Regression and progression between the various states is based on published data. Because the topic of our review was suggested to the Agency for Health Care Policy and Research by the American College of Obstetricians and Gynecologists (Washington, DC), we used US data as much as possible for our probability and prevalence estimates.
Assumptions of the model
To produce a model with a manageable number of possible outcomes, some simplifying assumptions were necessary. The following list outlines the main underlying assumptions of the model and our rationale for making them.
1. The model assumes that all cases of cervical cancer begin with HPV infection. We incorporated HPV status into the model for two reasons. First, although a small percentage of cervical cancers do not contain detectable HPV DNA, even with sensitive assays there is consensus that HPV infection is die causative agent for the vast majority of cervical cancers (5, 6, 18, 19) . Second, certain HPV types clearly are more likely to progress to cancer than others, and identification of these types in cervical cells may help determine optimal diagnostic and treatment strategies for patients wim abnormal cervical smears (20) . Estimates of the age-specific incidence of HPV infection were derived from published cohort studies. For our model, the HPV infected state is defined as the presence of detectable HPV DNA with normal cervical cytology. Under the Bethesda System (21), cytologic changes consistent with HPV infection that do not meet the criteria for a diagnosis of cervical intraepithelial neoplasia (CTN) are classified as low-grade squamous intraepithelial lesions (SIL). 2. Studies that used older classification systems, primarily the one for CTN, were converted to the Bethesda System (21) as follows: cytologic evidence of HPV infection and CIN I = low-grade SIL; CIN II, CIN HI, and carcinoma in situ = high-grade SIL. 3. Regression of HPV is defined as the inability to detect a previously detected HPV viral type in the same patient by using the same diagnostic techniques. Published regression rates, usually expressed as percentage of infections per time period, and progression rates to low-grade SIL and high-grade SIL were converted to transition probabilities (22). 4. Similarly, regression and progression probabilities for low-grade SIL and high-grade SIL were derived from the literature. Low-grade SIL lesions were allowed to regress to both latent HPV infection and the Well state, and high-grade SIL lesions were allowed to regress to low-grade SIL, HPV, and WeU. 5. Base-case estimates for incidence, regression, and progression rates were chosen on the basis of two criteria. First, parameters were adjusted to result in predicted age-specific prevalence rates for HPV, low-grade SIL, and high-grade SIL and age-specific incidence of cervical cancer that were within the range reported in cross-sectional data. Second, because we planned to use the model as the basis of a cost-effectiveness analysis of screening strategies (16), we chose estimates that resulted in cervical cancer incidences that would bias the cost-effectiveness model in favor of improving screening sensitivity. Thus, our base-case estimates result in peak cervical cancer incidence biased toward higher values at earlier ages. 6. We include a hysterectomy state, since removal of the organ at risk clearly affects calculation of cervical cancer incidence (23, 24) . However, we did not correct for hysterectomy in our natural history model, since population-based registries do not make a similar correction. We did test the impact of hysterectomy on our estimates.
Model parameters
Incidence of HPV infection. The natural history of HPV infection is complex, and clearance and persistence of viral DNA, along with progression to SIL, vary depending on the viral type, patient characteris-tics such as age and immune status, and study design and assay methods (5, 6, 18, 19, 25) . We do not distinguish between different types of HPV; our incidence, progression, and regression estimates are averages for all viral types. The risk of developing cervical cancer after infection is clearly related to HPV type. Our baseline estimates for HPV and low-grade SIL prevalence also are lower than reported in studies of cervical smears in adolescents (26, 27) . However, since we modeled an entire population and not just those who are sexually active, prevalence should be lower than for only those who are sexually active. Table 2 shows the baseline age-specific estimates and ranges for the sensitivity analysis of HPV incidence in the model. We varied the incidence rates by factors of 0.5-2 to examine the effects of changing HPV incidence on cervical cancer incidence in unscreened populations. We also varied the age of peak incidence from 20 to 30 years to examine the effects of a later onset of sexual activity on age-specific cervical cancer incidence.
Regression, persistence, and progression of HPV infection. Estimates of regression and progression
rates of HPV infection are subject to variability in study design, patient population, and viral assay techniques. Reported regression rates for prevalent cases include 70 percent after 2 years for a cohort of adolescents and college-age women (26) , 68 percent over 14 months for women less than age 25 years, and 35 percent for women more than age 30 years (28). Ho et al. (27) reported a 1-year regression rate of 70 percent for their incident cases. All of these results were for women whose cytology was normal. The overall regression rate in a large Finnish cohort was 42.8 percent over 50 months (29, 30) . However, the disease status in this group was determined on the basis of cytologic evidence of HPV infection. Under the Bethesda System (21), these abnormalities would be classified as low-grade SIL.
Progression probabilities are also difficult to determine. Moscicki et al. Progression rate (HPV to low-grade SIL) (26, 28, 31) Proportion of infections progressing directly to high-grade SIL (26, 28, 31) Regression rate (age (years)) (low-grade SIL to HPV or Well) (27, (32) (33) (34) 
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Proportion of low-grade SIL reverting to Well (27, (32) (33) (34) Progression rate (age (years)) (low-grade SIL to highgrade SIL (27, (32) (33) (34) 
Regression rate (high-grade SIL to low-grade SIL or Well) (27, (32) (33) (34) Proportion of high-grade SIL reverting to Well (27, (32) (33) (34) Progression rate (high-grade SIL to stage I cancer 2-year cumulative incidence of high-grade SIL of 28 percent in women with HPV DNA; only 36 percent of these women had had a prior low-grade SIL smear. Consistent with our other estimates, our base-case estimates (table 2) were derived from the higher end of the reported ranges. Cases that progress directly to high-grade SIL are similar to the "rapidly progressive" cases used in other models (9) . Again, we varied age-specific regression rates to produce an agespecific cancer incidence curve similar to that seen in unscreened populations.
Low-grade and high-grade squamous intraepithelial neoplasia. Determining transition probabilities from the literature that accurately reflect natural history is as difficult for SIL as it is for HPV infection. The difficulties in converting rates collected over varying, often-unspecified times and in heterogeneous populations are further magnified by differences in terminology. For example, many studies report transitions from HPV-associated cytologic changes to CIN I to CIN II to CIN HI to carcinoma in situ, which may be difficult to translate into the Bethesda System (21) terminology of low-grade SIL and high-grade SIL. Our model assumes an age dependence in regression and progression rates (28, 32, 33) . For our baseline case, we use the estimates of Syrjanen et al. (34) , the largest cohort that reports results by using the Bethesda System. The length of time for high-grade SIL progression is more difficult to estimate from these data than are the other parameters; in this cohort, all patients who progressed to carcinoma in situ, according to an older classification system, were treated. Prior models have estimated the duration from severe dysplasia/carcinoma in situ to invasive cancer as 10-15 years. We used 12 years for the base case (table 2), since this interval resulted in an age-specific incidence of cervical cancer most consistent with observed data.
Natural history of invasive cancer. Almost no data exist for estimating the rates of progression from stage I through stage IV cervical carcinoma. There is also no way to determine the likelihood of developing symptoms. Since distribution of cases by stage in an unscreened population should be a function of both the progression rate and the likelihood of presentation with symptoms (since incident cases would be detected only upon presentation with symptoms), we adopted the approach taken by others (8, 9) . We adjusted these estimates by varying the progression rates and the probability of presentation with symptoms across previously reported ranges so the proportion of cases represented by each stage was similar to that for cervical cancer patients who have never been screened (35) (36) (37) (38) (table 3) . These values were chosen because they represent data from a wide range of facilities that treat women with cervical cancer and should be relatively representative of the range of current US practice. Five-year survival rates based on these data were as follows: stage I, 86.0 percent; stage n, 62.5 percent; stage HI, 37.9 percent; and stage IV, 11.3 percent.
We assumed no cancer-related mortality after 5 years. Although the Patterns of Care Evaluation data show some deaths after 5 years for all stages, they are relatively rare compared with the first 5 years. Other models also have used 5-year survival. These data are disease specific; therefore, patients are also at risk for other causes of death during the 5-year postdiagnosis period.
Mortality from other causes. Mortality from causes other than cervical cancer was estimated by subtract- ing age-specific cervical cancer mortality rates from age-specific all-cause mortality rates by using US life tables from 1995 (41) .
Hysterectomy for benign disease. We used agespecific hysterectomy rates obtained from the National Hospital Discharge Survey (42) and Maryland discharge data (43) 
Sensitivity and specificity of cervical smears. We performed a meta-analysis of studies of conventional cervical smears, using colposcopy and histology as the reference standard (16) . When we used a cytologic threshold of Atypical Squamous Cells of Uncertain Significance or higher and a histologic threshold of low-grade SIL or higher, we found a sensitivity of 51 percent and a specificity of 97 percent. These values were similar to those found in a previously published meta-analysis (44) . We used these values to test the impact of screening at 1-, 2-, 3-, and 5-year intervals on the age-specific incidence of cervical cancer.
RESULTS

Age-specific prevalence of HPV and SIL
The age-specific prevalence of HPV infection in women whose cytology is normal, predicted by the model in which base-case estimates are used, is shown in figure 2 , which also illustrates the predicted agespecific prevalence of low-grade and high-grade SIL lesions. The model predicts peak prevalences of HPV of 24.7 percent at age 21 years, low-grade SIL of 8.3 percent at age 28 years, and high-grade SIL of 2.6 percent at age 42 years.
Age-specific Incidence of cervical cancer Figure 3 shows the age-specific incidence of cervical cancer predicted by the base-case model parameters. The peak incidence is 81/100,000 at age 48 years. The predicted distribution of cases by stage was as follows: stage 1,46.4 percent; stage n, 27.0 percent, stage El, 18.1 percent; and stage IV, 8.5 percent.
Sensitivity analyses
We tested the impact of varying the age-specific incidence of HPV from one-half to twice the base-case estimates. As shown in figure 4 , peak incidence and overall risk of cervical cancer varies with HPV incidence. Cancer incidence in younger women increases as HPV incidence increases, although the age of peak incidence does not change.
We also tested the impact of varying the prevalence of HPV and low-grade SIL at age 15 years on the subsequent incidence of cervical cancer (figure 5). We found that increasing the prevalence at younger ages without changing other parameters increases overall incidence and lowers the youngest ages at which cancer appears. FIGURE 5. Predicted effect of varying the prevalence of human papillomavirus (HPV) and low-grade squamous IntraepttheliaL lesions (LSIL) at age 15 years on subsequent cervical cancer incidence from 0% for both, 10% for HPV and 1% for LSIL, and 30% for HPV and 5% for LSIL
Changing the age of peak HPV prevalence from 20 to 30 years changed the curve for cervical cancer incidence, but the peak age remained the same. However, delaying the age of peak HPV incidence and decreasing the annual probability that women would present with early-stage cancer did move the peak incidence to later ages (figure 6).
Accounting for hysterectomy incidence lowered the overall population risk of cervical cancer, especially at later ages. However, the estimated risk for women with a cervix is higher than that based on population-based estimates (23) (figure 7).
We tested the impact of our natural history estimates on lifetime risk of cervical cancer in the absence of screening. Table 4 presents the parameters, the input range for sensitivity analysis, and the resulting range of lifetime cervical cancer risk. On the basis of our sensitivity analysis of these parameters, the model suggests that cervical cancer risk is most related to HPV incidence, to the proportion of HPV infections that progress directly to high-grade SIL, and to low-grade SIL progression rates. Changes in these parameters result in two-to threefold differences in cervical cancer risk. Changes in low-grade SIL regression rates and in high-grade SIL progression and regression rates resulted in 50-75 percent differences in cancer risk. The proportion of low-grade SIL lesions that regressed directly to the Well state instead of to the HPV state, and the proportion of high-grade SIL lesions that regressed to Well instead of to low-grade SIL, had minimal impact on cervical cancer risk.
Examples of model applications
We estimated the Lifetime risk of cervical cancer for women with no evidence of HPV DNA or SIL and with HPV, low-grade SIL, and high-grade SIL at various ages in the absence of further treatment. For a woman older than age 50 years who has no evidence of HPV infection, the risk of subsequent cervical cancer, even in the absence of screening, is less than 0.5 percent (figure 8).
We also tested the impact of screening at various intervals on the age-specific incidence of cancer ( figure  9 ). With screening every 5 years, incidence increased markedly in younger women. As screening frequency increased, the proportion of cases in younger women also increased: with no screening, 47.7 percent of cases occurred in women younger than age 50 years, while 68.1 percent occurred in women younger than age 50 years who were screened every year.
DISCUSSION
We developed a Markov model that, when estimates for HPV incidence, regression, and progression as well as for SIL regression and progression were used, resulted in a predicted age-specific incidence of cervical cancer similar to that seen in a number of unscreened populations (3, 45) . The age-specific prevalence of HPV and SIL also was similar to that reported in cross-sectional data. These prevalence figures are not inconsistent with cross-sectional data from a low-risk population in Portland, Oregon (46) . In this study, age-specific prevalences were 32. (47), who found asymmetric distributions skewed to younger ages for CIN I and CIN II and more normal distributions for higher grade lesions. The prevalences we found were also in the range reported by the National Breast and Cervical Cancer Early Detection Program, which targets underscreened, relatively highrisk women (48) . Because the model was initially developed to assess screening policies in the United States, we predominantly used US data for our model inputs. Future research should include validation of the model by using data from other populations. Our predicted age-specific incidence of cervical cancer in unscreened populations (figure 2) is similar to that reported in epidemiologic data. Data from multiple unscreened populations show a striking similarity in the pattern of age-specific incidence (1, 3, 45) . Gustafsson et al. (45) described two separate curves, one with a peak incidence between ages 40 and 50 years with a more rapid decline and one with a peak incidence between ages 50 and 65 years with a more gradual decline. Their modeling suggests that some of this difference results from increased incidences in successive birth cohorts. The curves with peaks at earlier ages were observed primarily for western European countries between 1950 and 1975. The curves showing a later peak incidence are from either third-world countries or western countries in the 1930s and 1940s. Some of the difference in age-specific incidence may be due to differences in age at onset of sexual activity, number of partners, or overall prevalence of HPV in the sexually active population. Since incidence in unscreened populations also is a function of the likelihood of presenting with symptoms, some of the observed differences may be due to variations in access to care, or willingness to seek care, across time and place.
Our predicted distribution of cancer by stage also was similar to that reported in series of cases with no prior screening (35) (36) (37) (38) .
The incidence of HPV infection, the proportion of rapidly progressive infections, and low-grade SIL progression rates appear to have the largest impact on cervical cancer risk. This finding suggests the potential impact of primary prevention of HPV infection, by using either barrier methods of contraception, vaccination, or abstinence, on cervical cancer risk. Further refinement of the model will enable modeling of the effectiveness and cost-effectiveness of such strategies. The model also can be used to investigate the impact of testing for high-risk HPV types in screening strategies (49) . It could even be adapted to model the impact of the probability of specific mutations in HPVinfected cells on cervical carcinogenesis.
Because multiple parameters can affect the predicted incidence of cervical cancer, similar results could be obtained by combining the estimates for the various natural history probabilities differently. Because our initial goal in constructing the model was to use it to analyze the cost-effectiveness of new technologies for improving the sensitivity of cervical smears (16), we chose estimates that resulted in a predicted age-specific incidence that would favor improved sensitivity (early age of peak incidence, relatively high progression rates). Given the range of reported estimates for natural history probabilities, our estimates clearly will not reflect the natural history of HPV infection in all populations. Our predicted prevalence patterns of HPV and SIL are similar to those reported in cross-sectional studies of average-risk populations (46, 47) . The model does not predict a second peak in HPV in women later in life, after age 35 years, as was suggested in some studies (38, 50) . Because cross-sectional data represent the prevalence in successive birth cohorts, it is likely that at least some of this second peak may be due to age differences in onset of sexual activity or other risk factors in different cohorts. We chose a cohort simulation for computational simplicity and speed. The impact of varying specific parameters in different cohorts on cross-sectional data could be tested easily by using our basic model.
Many of the parameters, especially those related to regression and progression, are reported as means. As Carson and DeMay (47) tribution of low-grade lesions does not appear to be Gaussian, a finding that our model recreates. More complete reporting of distributions would enable more sophisticated modeling techniques that incorporate the actual distribution of parameter estimates, in turn allowing more precise estimates of the range of cervical cancer risk.
The model can be used to predict individual risk of cervical cancer given a patient's age and histologic diagnosis ( figure 8 ). Varying the model to incorporate the distribution of various input parameters could enable the risk to be expressed as a point estimate with confidence intervals. Incorporation of patient preferences for various treatment and follow-up options could make the model useful for patient counseling.
Another application is in testing the impact of screening and prevention strategies on cervical cancer incidence. For example, the dramatic effect of decreasing HPV incidence on cancer incidence (figure 4) suggests the potential impact of effective HPV vaccines. Assessing the effect of screening on age-specific incidence (figure 9) is another example.
A third application is in exploring the effect of deriving incidence estimates from populations with varying degrees of screening, as is common in the United States. For example, the widely cited Eddy (9) Markov model has served as the basis for several cost-effectiveness analyses (9, 51) . Although Eddy's model parameters were adjusted to fit international data (52), the incidence of invasive cervical cancer in an unscreened US population was estimated by assuming that it would be three times higher than that observed in a partially screened population. However, this assumption does not account for the fact that 30-50 percent of US cancer cases occur in an unscreened population. Because the incidence of cervical cancer in the United States reflects both screened and unscreened populations as well as the effect of different cohorts with varying exposure to HPV, simply increasing the age-specific incidence by threefold will overestimate the expected incidence in unscreened patients at younger ages. If the distribution of stages is not changed, then the ratio of incidence to mortality will be overestimated; the ratio of early-stage cases in the SEER registries is much higher in younger women than in older women (66 percent localized in women less than age 50 years compared with 37 percent in women more than age 50 years) (2).
We were able to approximate the lifetime cervical cancer risk of Eddy (2.5 percent) (9) by altering our HPV incidence. However, the lifetime mortality risk predicted by this model is 0.88 percent, substantially lower than Eddy's estimate of 1.18 percent. We then adjusted rates for progression between cancer stages and symptoms to obtain similar incidence and mortality risks. By changing the progression rates to 90 percent in 2.5 years for stage I to stage II, 75 percent in 1 year from stage II to stage m, and 100 percent in 1 year for stage m to stage IV and changing the probability of symptoms for stage III to 35 percent, we obtained a lifetime risk of 2.52 percent and a mortality risk of 1.14 percent. However, these progression rates are inconsistent with those reported by Eddy.
Because detection of cervical cancer in younger women included in the SEER data is more likely to be due to screening and therefore occurs at both an earlier age and an earlier phase of progression than in older women, survival rates are likely to be higher than for women who present with symptoms. The high incidence-to-mortality ratio of the Eddy model (9) may be secondary to extrapolations of distribution by stage in unscreened populations to the SEER data for younger women. Use of our model to examine the effects of different screening intervals also supports this hypothesis: as screening intervals decrease, the proportion of early-stage disease increases, as does the proportion of cases among younger women (figure 9), a finding that has been reported in the British population (53) . This prediction of the model is also consistent with the finding that in younger women, "rapid-onset" cervical cancer tends to be early-stage disease (54) . In addition, we have been able to recreate observed SEER incidence and mortality data by modeling a cohort with varying proportions of screening intervals, from no screening over a lifetime to annual screening (16) .
These comparisons illustrate the difficulty in estimating the risk of cancer in unscreened populations when most available data represent both screened and unscreened populations. Previous models have used estimates from case-control or cohort studies (33, 52) . However, the consistency of the shape of the curve for age-specific incidence in unscreened women across populations (1, 45) facilitates calibration of the model. Other than the paper of Gustafsson and Adami (55), we are unaware of another model that takes a similar approach.
Similarly, relatively few published models of cervical cancer screening incorporate the HPV status of normal women (49, 56, 57) , and one includes the HPV status of women infected with human immunodeficiency virus (58) . Given the prevalence of HPV, the growing insight into its molecular biology, and the potential role of HPV testing in preventive strategies, modeling cervical cancer prevention strategies in the future may well require some method for incorporating HPV status.
Obvious limitations inherent in any model are uncertainty surrounding parameter estimates, assumptions that can be reasonably debated, and the effects of changing epidemiologic parameters over time and space. In addition, the specific parameters of our model are based on US data. We used Federation Internationale de Obstetriques et Gynecologie staging of cervical cancer and calculated survival rates on the basis of published US data. Although use of these stages improves the clinical relevance of the model, stage-specific survival may well vary in other settings. Similarly, the effect of hysterectomy rates, a particularly important parameter in assessing the efficiency of screening strategies, may not be as important in other settings in which hysterectomy is not used as widely.
In summary, we have developed a model that synthesizes published data on HPV infection and cervical carcinogenesis and approximates reported patterns of age-specific incidence and prevalence. The model is designed to be updated easily as new evidence becomes available and enables modeling of both hypotheses about the biologic behavior of HPV-related disease and the potential impact of various strategies for preventing cervical cancer. Strategies that reduce HPV incidence can reduce cervical cancer incidence at least as much as strategies that improve the availability or sensitivity of cytologic screening. Given the importance of models in understanding the biology, epidemiology, and policy implications of HPV infection and cervical carcinogenesis, serious consideration should be given to development of a consensus model, or a series of models, for general use.
